diaDexus, Inc. (DDXS) Reports Strong Year-over-Year Growth for Q1 2012
diaDexus, based in South San Francisco, California, is focused on the development and commercialization of proprietary cardiovascular diagnostic products addressing unmet needs in cardiovascular disease. DDXS is the successor to a company initially formed as a joint venture between SmithKlineBeecham Corporation and Incyte Pharmaceuticals, Inc. Upon formation, SmithKlineBeecham Corporation granted DDXS an exclusive license to certain diagnostic intellectual property, including Lp-PLA2, an inflammatory marker of cardiovascular risk. DDXS markets two primary products, one in the United States and one in Europe. In the United States, the company’s PLAC® Test ELISA Kit is the only blood test cleared by the FDA…